Health Canada approves first atopic dermatitis biologic drug for children aged 6 and older
ESC is pleased to share the news that Health Canada has approved dupilumab (brand name Dupixent®) the first biological drug for the treatment of moderate to severe atopic dermatitis (AD) in children aged 6 years and older whose condition is not adequately controlled with topical prescription therapies. Dupilumab was previously approved for patients aged 12 and older.
Was your child recently part of a clinical trial for dupilumab? If so, ESC wants to hear from you. We are gathering anonymous input on patient experiences with clinical trial medications to submit as part of the Canadian Health Technology Assessment (HTA) process, which helps inform decisions around drug reimbursement in Canada.
If you would like to share your experience and help demonstrate the burden of this condition and the needs of our community, please contact us at [email protected] today.
To view the press release from Sanofi, the distributor of Dupixent, click here.